Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Regulation of Expression Occurs at Multiple Steps

Regulation of Expression Occurs at Multiple Steps

Gene expression can be regulated at almost every step from gene to protein. Transcription is the step that is most commonly regulated. This involves the binding of proteins to short regulatory sequences on the DNA. This association can either promote or inhibit the transcription of a gene associated with the respective sequence.
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...

Translational Regulation

Translational Regulation

Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mechanisms of resistance to macrophage checkpoint inhibitors in B-cell non-Hodgkin lymphoma.

British journal of haematology·2026

Same author

Targeting eIF4A-dependent translation in genetically complex sarcoma.

JCI insight·2026

Same author

In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment.

Cell reports·2026

Same author

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Spatial genomics reveals cholesterol metabolism as a key factor in colorectal cancer immunotherapy resistance.

Frontiers in oncology·2025

Same author

SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.

The Journal of experimental medicine·2024

Search research articles

Related Experiment Video

Updated: Jul 1, 2026

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Translational control and cancer therapy.

Konstantinos J Mavrakis¹, Hans-Guido Wendel

¹Cancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

Cell Cycle (Georgetown, Tex.)

|September 13, 2008

Summary

Rheb and eIF4E are key regulators of protein translation in cancer. Targeting Rheb with farnesyltransferase inhibitors shows therapeutic potential in certain tumors by blocking oncogenic pathways.

Area of Science:

Oncology
Molecular Biology
Cancer Research

Background:

Translational control is critical in cancer development.
Rheb, a proximal activator of mTORC1, influences protein translation.
Oncogenic factors like c-Myc and eIF4E are implicated in tumorigenesis.

Purpose of the Study:

To investigate the role of Rheb in cancer.
To explore the therapeutic implications of targeting Rheb.

Main Methods:

In vivo tumorigenesis models.
Analysis of Rheb expression in human cancers.
Assessment of mTORC1 activation and rapamycin sensitivity.
Evaluation of farnesyltransferase inhibitors (FTIs) on Rheb activity.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Quantitative Immunofluorescence to Measure Global Localized Translation

Quantitative Immunofluorescence to Measure Global Localized Translation

Published on: August 22, 2017

Related Experiment Videos

Last Updated: Jul 1, 2026

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Quantitative Immunofluorescence to Measure Global Localized Translation

Quantitative Immunofluorescence to Measure Global Localized Translation

Published on: August 22, 2017

Main Results:

Rheb cooperates with c-Myc in tumorigenesis, similar to Akt or eIF4E.
Rheb is highly expressed in lymphomas and other cancers.
Cancer-related Rheb activities are mTORC1-dependent and rapamycin-sensitive.
FTIs directly inhibit Rheb activity, mediating therapeutic effects in tumors.

Conclusions:

Translational control mechanisms are significant contributors to oncogenesis.
Targeting Rheb with FTIs offers a potential therapeutic strategy for specific cancers.
Understanding Rheb's role in translational control can guide future cancer therapies.